Copaxone

Options investors are betting against Teva Pharmaceutical Industries. And as  Bloomberg  reports, that fact doesn't surprise some analysts. Teva's new CEO, Jeremy Levin, unveiled his strategy last month--and that plan failed to quell shareholders' fears, they say.

With $4 billion of Copaxone revenue on the line, it's no surprise to find Teva waving a red flag to the FDA as Biogen Idec gets down to the regulatory wire with its closely watched competitor BG-12. The big generics company filed a petition with the FDA demanding an advisory committee meeting to inspect what it has called potentially "serious safety risks."

Teva Pharmaceutical Industries ($TEVA) is very proud of its multiple sclerosis drug Copaxone. Thing is, Copaxone goes off patent in 2015.

Teva Pharmaceutical Industries ($TEVA) has scrapped its $300 million plans for a warehouse and IT center in Philadelphia. The planned three-building complex, much anticipated by city leaders, is another casualty of CEO Jeremy Levin's restructuring.

Today's news that European regulators had slapped down an application from Genzyme and Isis to market their antisense drug Kynamro underscored many of the lingering concerns that have plagued this research field for years. But at Cowen, all the doubts about antisense drugs make this sector ripe for a potential surprise breakout that could significantly readjust some long-standing industry attitudes.

Teva Pharmaceuticals ($TEVA) has money in the bank, drugs in the pipeline and big plans for the future. Given those assets and four more years, CEO Jeremy Levin told investors on Tuesday they will have a whole new Teva.